Medtronic Reveals Plans For Next-Generation ‘Drug-Filled’ Stent
This article was originally published in The Gray Sheet
The firm characterizes the early-stage technology as its answer to Abbott’s bioabsorbable vascular scaffold and Boston Scientific’s bioabsorbable polymer coronary stents.
You may also be interested in...
Covidien's Pipeline aneurysm device shows 8.5% major complication rate in early post-market results. Surprise at long-term results for endovascular repair of abdominal aortic aneurysms. More clinical trial news.
Recent debuts include NuVasive’s PCM cervical disk system, Boston Scientific’s bioabsorbable Synergy drug-eluting stent in Europe and Medtronic’s MRI-safe Advisa pacemaker in Japan.
Recent launches and approvals include overseas debuts of Abbott’s Absorb bioabsorbable vascular scaffold and Medtronic’s next-generation CoreValve Evolut transcatheter aortic heart valve.